Seroepidemiology of mumps in Europe (1996-2008): why do outbreaks occur in highly vaccinated populations?

PubWeight™: 1.06‹?› | Rank: Top 15%

🔗 View Article (PMID 22687578)

Published in Epidemiol Infect on June 12, 2012

Authors

J Eriksen1, I Davidkin2, G Kafatos3, N Andrews3, C Barbara4, D Cohen5, A Duks6, A Griskevicius7, K Johansen8, K Bartha9, B Kriz10, G Mitis11, J Mossong12, A Nardone3, D O'Flanagan13, F DE Ory14, A Pistol15, H Theeten16, K Prosenc17, M Slacikova18, R Pebody3

Author Affiliations

1: European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
2: National Institute for Health and Welfare (THL), Helsinki, Finland.
3: Health Protection Agency Health Protection Services Colindale, London, UK.
4: Mater Dei Hospital, Malta.
5: School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Israel.
6: Laboratory of the State Agency Infection Centre, Virology Unit, Riga, Latvia.
7: National Public Health Surveillance Laboratory, Vilnius, Lithuania.
8: Swedish Institute for Infectious Disease Control, Stockholm, Sweden.
9: National Centre for Epidemiology, Budapest, Hungary.
10: National Institute of Public Health (SZU), Prague, Czech Republic.
11: Nicosia Hospital, Nicosia, Cyprus.
12: Surveillance & Epidemiology of Infectious Diseases, Laboratoire National de Santé, Luxembourg.
13: Health Protection Surveillance Centre, Dublin, Ireland.
14: Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
15: National Centre for Communicable Diseases Surveillance and Control, National Institute of Public Health, Romania.
16: Center for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute (Vaxinfectio), University of Antwerp, Belgium.
17: Laboratory for Virology, NPHI, Slovenia.
18: Public Health Authority of the Slovak Republic, Bratislava, Slovak Republic.

Articles citing this

Estimates of mumps seroprevalence may be influenced by antibody specificity and serologic method. Clin Vaccine Immunol (2013) 0.89

Underreporting of viral encephalitis and viral meningitis, Ireland, 2005-2008. Emerg Infect Dis (2013) 0.89

Susceptibility to measles, mumps, and rubella in 5-year-old children in Flanders, Belgium. Eur J Pediatr (2015) 0.86

Environmental factors potentially associated with mumps transmission in yeshivas during a mumps outbreak among highly vaccinated students: Brooklyn, New York, 2009-2010. Hum Vaccin Immunother (2013) 0.85

Characteristics of a large mumps outbreak: Clinical severity, complications and association with vaccination status of mumps outbreak cases. Hum Vaccin Immunother (2015) 0.84

Seroprevalence of antibodies against measles, rubella, mumps, varicella-zoster, and B. Pertussis in young adults of Madrid, Spain. Hum Vaccin Immunother (2013) 0.81

Outbreak-related mumps vaccine effectiveness among a cohort of children and of young adults in Germany 2011. Hum Vaccin Immunother (2013) 0.78

Viral etiology of mumps-like illnesses in suspected mumps cases reported in Catalonia, Spain. Hum Vaccin Immunother (2014) 0.78

Seroprevalence of IgG Antibodies against Mumps in Bulgarian Children under 18 Years of Age. Balkan Med J (2013) 0.75

Application of Oral Fluid Assays in Support of Mumps, Rubella and Varicella Control Programs. Vaccines (Basel) (2015) 0.75

Challenges in Interpretation of Diagnostic Test Results in a Mumps Outbreak in a Highly Vaccinated Population. Clin Vaccine Immunol (2017) 0.75

Are cases of mumps in vaccinated patients attributable to mismatches in both vaccine T-cell and B-cell epitopes?: An immunoinformatic analysis. Hum Vaccin Immunother (2013) 0.75

Mumps Virus SH protein inhibits NF-κB activation by interacting with TNFR1, IL-1R1, and TLR3 complexes. J Virol (2017) 0.75